Zilebesiran
RNA / oligonucleotide
Also known as RG6615
Evidence outlook · registrational
Hypertension: registrational readout pending
Entered Phase 3 on reliable signal mid-stage evidence. Registrational readout expected around 2030-09-23. The sponsor reported topline results of a Phase 2 study on 2025-08-30 (KARDIA-3 (zilebesiran add-on) did not meet its pre-specified significance definition); that is not the registrational readout.
KARDIA-1 (NCT04936035): The study randomized 394 participants to placebo or zilebesiran and maintained quadruple blinding, with approximately 60–75 participants per treatment group analyzed for the primary endpoint. The primary clinical endpoint—change in 24-hour ambulatory systolic blood pressure at Month 3—was significantly favorable for zilebesiran versus placebo, supporting strong evidence from this trial.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ZENITH NCT07181109 · High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk Registry: NCT07181109 | 3 | Time to First Occurrence of a Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, or Heart Failure (HF) Event (Hospitalization for HF or Urgent HF Visit) (Up to approximately 5 years) 2030-09-23 | In progress: results expected 23 Sept 2030 | not yet graded | link ↗ |
View 1 more trial
KARDIA-1 NCT04936035 · Hypertension The study randomized 394 participants to placebo or zilebesiran and maintained quadruple blinding, with approximately 60–75 participants per treatment group analyzed for the primary endpoint. The primary clinical endpoint—change in 24-hour ambulatory systolic blood pressure at Month 3—was significantly favorable for zilebesiran versus placebo, supporting strong evidence from this trial. Registry: NCT04936035 | 2 | Change From Baseline at Month 3 in 24-hour Mean SBP Assessed by ABPM (Baseline and Month 3) 2023-04-04 | Change From Baseline at Month 3 in 24-hour Mean SBP Assessed by ABPM (Baseline and Month 3): Placebo 6.8 millimeters of mercury (mmHg) ± 1.58 vs Zilebesiran 150 mg Q6M -7.3 millimeters of mercury (mmHg) ± 1.49 vs Zilebesiran 300 mg Q6M and Q3M -10.0 millimeters of mercury (mmHg) ± 1.05 vs Zilebesiran 600 mg Q6M -8.9 millimeters of mercury (mmHg) ± 1.52; p=<0.0001 (Placebo vs Zilebesiran 300 mg Q6M and Q3M), p=<0.0001 (Placebo vs Zilebesiran 600 mg Q6M) | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (1)
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (2)
What this study did
What this study did
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 2 (1)
What this study did
Competitive landscape
Other Angiotensinogen (AGT) drugs
IBI3016, QCZ484, Tonlamarsen, ADX-850. Compare all 5 Angiotensinogen (AGT) drugs
4 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Hypertension: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Zilebesiran: this drug | Phase 3 | RNA / oligonucleotide | Angiotensinogen (AGT) | Reliable signal | NCT04936035: Change From Baseline at Month 3 in 24-hour Mean SBP Assessed by ABPM (Baseline and Month 3): Placebo 6.8 millimeters of mercury (mmHg) ± 1.58 vs Zilebesiran 150 mg Q6M -7.3 millimeters of mercury (mmHg) ± 1.49 vs Zilebesiran 300 mg Q6M and Q3M -10.0 millimeters of mercury (mmHg) ± 1.05 vs Zilebesiran 600 mg Q6M -8.9 millimeters of mercury (mmHg) ± 1.52; p=<0.0001 (Placebo vs Zilebesiran 300 mg Q6M and Q3M), p=<0.0001 (Placebo vs Zilebesiran 600 mg Q6M) | |
| Aprocitentan (Tryvio) | Approved | Small molecule | Endothelin receptor (ETA/ETB, dual) | Reliable signal | NCT03541174: Week 4 sitting systolic blood pressure change: -15.26 vs -11.47 mmHg placebo for aprocitentan 12.5 mg; difference -3.79 mmHg (p=0.0042). For aprocitentan 25 mg: -15.20 vs -11.47 mmHg placebo; difference -3.73 mmHg (p=0.0046). | |
| Baxdrostat (Baxfendy) | Approved | Small molecule | Aldosterone synthase (CYP11B2) | Reliable signal | NCT06168409: Change in 24-hour ambulatory average SBP at week 12: -16.6 mmHg with baxdrostat vs -2.6 mmHg with placebo; between-group difference -14.0 mmHg (95% CI -17.2 to -10.8; p<0.0001). NCT06034743: Change From Baseline in Seated Systolic Blood Pressure for 2 mg Baxdrostat (At Week 12): Double-Blind Treatment Period Weeks 0-12 Baxdrostat 2mg -15.7 mmHg (Standard Error 1) vs Double-Blind Treatment Period Weeks 0-12 Placebo -5.8 mmHg (Standard Error 1) | |
| Propranolol (Inderal LA) | Approved | Small molecule | Beta-1/beta-2 adrenergic receptors | not yet graded | No reviewed efficacy summary in this indication | |
| AD-209 | Phase 3 | Small molecule | Angiotensin II type 1 receptor / L-type calcium channel / Na-Cl cotransporter | Partial signal | NCT06348576: Week-8 sitting systolic blood pressure: non-inferiority and superiority vs telmisartan 40 mg confirmed in the full analysis set (published Phase III, 2026-02-20). | |
| AGSAVI | Phase 3 | Small molecule | Angiotensin II receptor / Calcium channel / Thiazide-like diuretic | Partial signal | No reviewed efficacy summary in this indication | |
| Amlodipine / Valsartan / Rosuvastatin (CJ-30060) | Phase 3 | Small molecule | Angiotensin II receptor / Calcium channel / HMG-CoA reductase | Partial signal | No reviewed efficacy summary in this indication | |
| DWC202206 + DWC202207 | Phase 3 | Small molecule | — | Partial signal | No reviewed efficacy summary in this indication | |
| Esaxerenone (Minnebro) | Phase 3 | Small molecule | Mineralocorticoid receptor | Partial signal | NCT02722265: Change from baseline in sitting SBP/DBP, overall population (n=368): -16.1/-7.7 mmHg at week 12, -18.9/-9.9 mmHg at week 28, -23.1/-12.5 mmHg at week 52 (all 95% CI given); monotherapy subgroup (n=245): -16.3/-7.0 mmHg at week 12, -23.7/-12.3 mmHg at week 52 NCT02807987: Change from baseline in sitting SBP/DBP at end of treatment (Week 12), add-on-to-ARB/ACEI group (n=58): -17.8 mmHg SBP (95% CI -21.0 to -14.7), -8.1 mmHg DBP (95% CI -9.7 to -6.5), p<0.001 | |
| Fimasartan / Atorvastatin / Ezetimibe (BR1017) | Phase 3 | Small molecule | AT1 receptor; NPC1L1; HMG-CoA reductase | Partial signal | NCT05930028: Week 8 co-primary endpoints (full analysis set, 148 randomized): mean sitting systolic BP, fimasartan + atorvastatin/ezetimibe vs atorvastatin/ezetimibe, LS mean difference -7.26 mm Hg (95% CI -12.91 to -1.61), P = 0.0124; LDL-C percent change, fimasartan + atorvastatin/ezetimibe vs fimasartan, LS mean difference -58.02% (95% CI -66.03 to -50.02), P < 0.0001 (Hong et al., Clin Ther 2025). | |
| Levamlodipine / Valsartan (SYH9056) | Phase 3 | Small molecule | Angiotensin II type 1 receptor / L-type calcium channel (dual) | Partial signal | NCT06771245: Blood-pressure lowering significantly superior to levamlodipine or valsartan monotherapy (sponsor, 2026-06-16). | |
| Lorundrostat | Phase 3 | Small molecule | Aldosterone synthase (CYP11B2) | Reliable signal | NCT06153693: Launch-HTN: change from baseline in automated office SBP at Week 6, lorundrostat 50 mg vs placebo: -16.9 mmHg absolute reduction; -9.1 mmHg placebo-adjusted reduction (p<0.0001) NCT05769608: Placebo-adjusted change in 24-hour average ambulatory SBP at Week 12: -7.9 mmHg (lorundrostat 50 mg arm) | |
| Olmesartan / Rosuvastatin (DWJ1276) (Olostar) | Phase 3 | Small molecule | Angiotensin II receptor / HMG-CoA reductase | Partial signal | NCT01764295: LDL-C percent change from baseline at week 8 (LS mean, SE): DWJ1276 (FDC) -52.3% (2.8%) vs olmesartan alone -0.6% (3.5%) vs rosuvastatin alone -46.9% (3.5%) vs placebo -3.2% (3.9%); FDC vs olmesartan difference -51.7% (95% CI -59.8% to -43.6%, P<0.0001). | |
| Orforglipron (Foundayo) | Phase 3 | Small molecule | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| QR12000 | Phase 3 | Small molecule | AT1R; neprilysin | Partial signal | No reviewed efficacy summary in this indication | |
| Sacubitril / Valsartan (Entresto) | Phase 3 | Small molecule | Neprilysin + Angiotensin II receptor (dual) | Partial signal | NCT01599104: Mean sitting systolic BP reduction from baseline at week 8 vs olmesartan (LCZ696/Entresto, Japanese essential hypertension): sacubitril/valsartan 200mg difference -5.01 mmHg (95% CI -6.95 to -3.06, P<0.001 for noninferiority and superiority); 400mg difference -6.97 mmHg (95% CI -8.92 to -5.03, P<0.001). NCT01593787: 43.8% (14/32) of patients reported at least one adverse event (mild severity; 0% serious AEs, 0% deaths); mean sitting SBP reduction 20.5±11.3 mmHg and mean sitting DBP reduction 8.3±6.3 mmHg from baseline to Week 8 (Total LCZ696 group, N=32); geometric mean UACR reduction 15.1%. | |
| Safiglipron (HRS-7535) | Phase 3 | Small molecule | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| SAL0120 | Phase 3 | Small molecule | Endothelin receptor type A (ETA) | not yet graded | No reviewed efficacy summary in this indication | |
| Valsartan / Amlodipine / Chlorthalidone (AJU-C52) | Phase 3 | Small molecule | Angiotensin II receptor / Calcium channel / Thiazide-like diuretic | Reliable signal | NCT06416865: Change in MSSBP from baseline to week 8: between-group difference of -10.99 (valsartan/amlodipine/chlorthalidone vs valsartan/amlodipine control) | |
| Vicadrostat | Phase 3 | Small molecule | Aldosterone synthase (CYP11B2) | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-9563 | Phase 2 | RNA / oligonucleotide | AGT (angiotensinogen) mRNA | not yet graded | No reviewed efficacy summary in this indication | |
| IBI3016 | Phase 2 | RNA / oligonucleotide | Angiotensinogen (AGT) | not yet graded | No reviewed efficacy summary in this indication | |
| QCZ484 | Phase 2 | RNA / oligonucleotide | Angiotensinogen (AGT) | not yet graded | No reviewed efficacy summary in this indication | |
| QLS1410 | Phase 2 | Small molecule | Aldosterone synthase (CYP11B2) | not yet graded | No reviewed efficacy summary in this indication | |
| RTN-001 | Phase 2 | Small molecule | PDE5 | not yet graded | No reviewed efficacy summary in this indication | |
| SAL0140 | Phase 2 | Small molecule | Aldosterone synthase (CYP11B2) | not yet graded | No reviewed efficacy summary in this indication | |
| Tonlamarsen | Phase 2 | RNA / oligonucleotide | Angiotensinogen (AGT) | Partial signal | NCT06864104: Co-primary 1, plasma angiotensinogen change to week 20: monthly tonlamarsen -67.2% vs single dose then placebo -23.0% (LS mean difference -44.1%, 97.5% CI -51.9% to -36.4%; P<0.0001), met. Co-primary 2, office systolic BP change to week 20: -6.7 vs -6.7 mm Hg (LS mean difference -0.1 mm Hg; P=0.97), missed. NCT05314439: (-6% v. -79%, PBO v. 90 mg, p=0.001); median AGT reductions (-5% v. -86%, PBO v. 90 mg) | |
| VB19055 | Phase 2 | Small molecule | Aldosterone synthase (CYP11B2) | not yet graded | No reviewed efficacy summary in this indication | |
| VCT220 | Phase 2 | Small molecule | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| BEBT-701 | Phase 1/2 | RNA / oligonucleotide | Angiotensinogen (AGT) / PCSK9 (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| ADX-850 | Phase 1 | RNA / oligonucleotide | Angiotensinogen (AGT) | not yet graded | No reviewed efficacy summary in this indication | |
| Carvedilol (CKD-385) | Phase 1 | Small molecule | Beta-adrenergic receptors (nonselective) and alpha-1 adrenergic receptor (antagonist) | Partial signal | No reviewed efficacy summary in this indication | |
| HJB647 | Phase 1 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| HS-10522 | Phase 1 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| JX09 | Phase 1 | Small molecule | Aldosterone synthase (CYP11B2) | Partial signal | No reviewed efficacy summary in this indication | |
| KK3910 | Phase 1 | Biologic (subtype unspecified) | — | not yet graded | No reviewed efficacy summary in this indication | |
| KN060 | Phase 1 | Monoclonal antibody | Factor XI/XIa (FXI/FXIa) | not yet graded | No reviewed efficacy summary in this indication | |
| LivaloV | Phase 1(overall) | Small molecule | HMG-CoA reductase / Angiotensin II type 1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Long-Acting ANP Analog (LY3971297) | Phase 1 | Peptide | Natriuretic peptide receptor (NPR-A) | not yet graded | No reviewed efficacy summary in this indication | |
| Nurandociguat | Phase 1 | Small molecule | Soluble guanylate cyclase | Weak signal | No reviewed efficacy summary in this indication | |
| SHR-4658 | Phase 1(overall) | Peptide | — | not yet graded | No reviewed efficacy summary in this indication | |
| C2402 | —(overall) | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Candesartan / Amlodipine | —(overall) | Small molecule | Angiotensin II type 1 receptor / L-type calcium channel | not yet graded | No reviewed efficacy summary in this indication | |
| DehydraTECH-CBD | —(overall) | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Lercanidipine | —(overall) | Small molecule | L-type calcium channels (Cav1.2) | not yet graded | No reviewed efficacy summary in this indication | |
| OLOMAX | —(overall) | Small molecule | Angiotensin II receptor / Calcium channel / HMG-CoA reductase | not yet graded | No reviewed efficacy summary in this indication | |
| Rosuampin | —(overall) | Small molecule | HMG-CoA reductase / Calcium channel | not yet graded | No reviewed efficacy summary in this indication | |
| N0877 | Discontinued | Small molecule | Angiotensin II receptor / Thiazide diuretic | not yet graded | No reviewed efficacy summary in this indication | |
| SER-100 | Discontinued | Peptide | ORL-1 (nociceptin opioid-like receptor) | Weak signal | Featured results are safety only in this race |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Zilebesiran to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2030 (1)
September 2030 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent